Summit Therapeutics PLC Sponsored ADR Stock News

Summit's ivonescimab showed a 48% reduction in disease progression risk in EGFR-mutant lung cancer — a best-in-class result in a tough-to-treat population. Overall survival data is trending positive but has not yet reached statistical significance; further follow-up may tip the balance. The recent stock sell-off reflects regulatory uncertainty rather than drug failure, creating a potential buyi...

Summit Therapeutics (NASDAQ: SMMT) experienced a significant 30% decrease in its stock on Friday, May 30th, closing at $18. This sudden decline came even though the stock had doubled within the past year, driven by favorable updates regarding its lung cancer medication, ivonescimab.

A new month has arrived. Investors now have a fresh opportunity to buy great stocks.

Shares of Summit Therapeutics (SMMT -30.39%) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an important clinical trial drove the stock down.

PFS in Phase 3 HARMONi study, using ivonescimab + chemotherapy to treat patients with EGFR 2nd-line NSCLC, was met with statistical significance, but OS was not. OS data not being met in a statistically significant manner puts doubt on company's ability to file a BLA of ivonescimab for the treatment of patients with EGFR 2nd-line NSCLC. The global non-small cell lung cancer therapeutics market ...

Shares of Summit Therapeutics (SMMT -27.85%) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning.

The trial was meant to answer the biggest question in biotech: What happens when U.S. companies test promising new Chinese cancer immunotherapies in western countries?

Summit Therapeutics stock plunged Friday after its highly watched cancer drug failed to significantly improve overall survival.